Prevention of Retinal Degeneration in a Rat Model of Smith-Lemli-Opitz Syndrome.

Prevention of Retinal Degeneration in a Rat Model of Smith-Lemli-Opitz Syndrome.
复制标题

预防史密斯 - 莱姆利 - 奥普茨综合征大鼠模型中的视网膜变性。

DOI:
10.1038/s41598-018-19592-8
复制
发表时间:
2018-01-19
期刊:
影响因子:
4.6
通讯作者:
Xu L
Xu L
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Fliesler SJ;Peachey NS;Herron J;Hines KM;Weinstock NI;Ramachandra Rao S;Xu L

文献摘要

参考文献

被引文献

相似文献

Smith-Lemli-Opitz综合征(SLOS)是一种隐性人类疾病,由DHCR 7(7-脱氢胆固醇还原酶)水平的胆固醇(CHOL)合成缺陷引起,DHCR 7通常催化7-脱氢胆固醇(7 DHC)转化为CHOL。在SLOS患者和用DHCR 7抑制剂AY 9944治疗的大鼠中发生7 DHC和7 DHC衍生的氧固醇的形成和异常积累。大鼠SLOS模型表现出进行性和不可逆的视网膜功能障碍和变性,其仅通过膳食CHOL补充部分改善。我们假设7 DHC衍生的氧固醇与这种视网膜变性有因果关系,阻断或减少它们的形成应使表型最小化。在这里,使用SLOS大鼠模型,我们证明了与CHOL加抗氧化剂(维生素E和C,加上亚硒酸钠)相结合的膳食补充剂在保护视网膜结构和功能以及降低7 DHC衍生的氧固醇形成方面比单独的膳食补充剂提供更好的结果。这些原理验证发现为设计使用CHOL-抗氧化剂联合治疗作为SLOS治疗的当前标准治疗的改进治疗干预的临床试验提供了转化的临床前框架。
Smith-Lemli-Opitz Syndrome (SLOS) is a recessive human disease caused by defective cholesterol (CHOL) synthesis at the level of DHCR7 (7-dehydrocholesterol reductase), which normally catalyzes the conversion of 7-dehydrocholesterol (7DHC) to CHOL. Formation and abnormal accumulation of 7DHC and 7DHC-derived oxysterols occur in SLOS patients and in rats treated with the DHCR7 inhibitor AY9944. The rat SLOS model exhibits progressive and irreversible retinal dysfunction and degeneration, which is only partially ameliorated by dietary CHOL supplementation. We hypothesized that 7DHC-derived oxysterols are causally involved in this retinal degeneration, and that blocking or reducing their formation should minimize the phenotype. Here, using the SLOS rat model, we demonstrate that combined dietary supplementation with CHOL plus antioxidants (vitamins E and C, plus sodium selenite) provides better outcomes than dietary CHOL supplementation alone with regard to preservation of retinal structure and function and lowering 7DHC-derived oxysterol formation. These proof-of-principle findings provide a translational, pre-clinical framework for designing clinical trials using CHOL-antioxidant combination therapy as an improved therapeutic intervention over the current standard of care for the treatment of SLOS.
DOI: 10.1203/pdr.0b013e31819ea4eb
发表时间: 2009-06
期刊: Pediatric research
影响因子: 3.6
作者:
Chan YM;Merkens LS;Connor WE;Roullet JB;Penfield JA;Jordan JM;Steiner RD;Jones PJ
通讯作者: Jones PJ
DOI: 10.1016/0042-6989(68)90041-2
发表时间: 1968-01-01
期刊: VISION RESEARCH
影响因子: 1.8
作者:
BROWN, KT
通讯作者: BROWN, KT
DOI: 10.1001/archopht.121.12.1738
发表时间: 2003-12-01
影响因子: --
作者:
Elias, ER;Hansen, RM;Fulton, AB
通讯作者: Fulton, AB
DOI: 10.1016/b978-0-12-401717-7.00029-0
发表时间: 2014-01-01
期刊: HANDBOOK OF NUTRITION, DIET, AND THE EYE
影响因子: --
作者:
Fliesler, Steven J.
通讯作者: Fliesler, Steven J.
DOI: 10.1007/s10545-007-0537-7
发表时间: 2007-06-01
影响因子: 4.2
作者:
Haas, D.;Garbade, S. F.;Burgard, P.
通讯作者: Burgard, P.